We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+8.27%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$21.8B
AUM Growth
+$3.36B
Cap. Flow
+$2.78B
Cap. Flow %
12.74%
Top 10 Hldgs %
12.04%
Holding
3,109
New
1,280
Increased
559
Reduced
519
Closed
699

Sector Composition

Rank Sector Weight
1 Healthcare 20.03%
2 Consumer Discretionary 13.15%
3 Technology 10.68%
4 Financials 9.81%
5 Communication Services 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NMCI
2326
DELISTED
Navios Maritime Containers L.P. Common Units
NMCI
$127K ﹤0.01%
+13,721
New +$94.3K
LPTH icon
2327
Lightpath Technologies
LPTH
$634M
$126K ﹤0.01%
+40,723
New +$155K
NFH
2328
DELISTED
New Frontier Health Corporation Ordinary Shares
NFH
$126K ﹤0.01%
11,162
-3,418
-23% -$34.7K
CTXR icon
2329
Citius Pharmaceuticals
CTXR
$14.1M
$123K ﹤0.01%
+2,755
New +$110K
MPC icon
2330
PUT
Marathon Petroleum
MPC
$89.8B
$123K ﹤0.01%
+2,300
New +$116K
PG icon
2331
CALL
Procter & Gamble
PG
$352B
$122K ﹤0.01%
+900
New +$117K
CALC icon
2332
CalciMedica
CALC
$11.7M
$121K ﹤0.01%
+1,563
New +$468K
TWI icon
2333
Titan International
TWI
$528M
$120K ﹤0.01%
12,916
-20,572
-61% -$161K
INTT icon
2334
inTEST
INTT
$160M
$119K ﹤0.01%
+10,069
New +$86.2K
BMTX
2335
DELISTED
BM Technologies, Inc.
BMTX
$118K ﹤0.01%
+10,117
New +$137K
CHRA
2336
DELISTED
Charah Solutions, Inc Common Stock
CHRA
$118K ﹤0.01%
+2,426
New +$91.4K
ORMP icon
2337
Oramed Pharmaceuticals
ORMP
$170M
$117K ﹤0.01%
11,563
-25,069
-68% -$206K
SIGA icon
2338
SIGA Technologies
SIGA
$221M
$117K ﹤0.01%
+17,987
New +$122K
CHNR icon
2339
China Natural Resources
CHNR
$4.55M
$114K ﹤0.01%
+1,561
New +$120K
PLYA
2340
DELISTED
Playa Hotels & Resorts
PLYA
$114K ﹤0.01%
+15,587
New +$103K
XOM icon
2341
PUT
ExxonMobil
XOM
$633B
$112K ﹤0.01%
+2,000
New +$105K
XTNT icon
2342
Xtant Medical Holdings
XTNT
$57.7M
$112K ﹤0.01%
+47,559
New +$102K
ARQ icon
2343
Arq
ARQ
$86.3M
$112K ﹤0.01%
+20,452
New +$115K
CX icon
2344
Cemex
CX
$17.4B
$110K ﹤0.01%
15,817
-1,035,767
-98% -$6.7M
TIO
2345
DELISTED
Tingo Group, Inc. Common Stock
TIO
$109K ﹤0.01%
52,828
+42,762
+425% +$97.3K
MA icon
2346
PUT
Mastercard
MA
$496B
$107K ﹤0.01%
+300
New +$105K
EXPE icon
2347
PUT
Expedia Group
EXPE
$35B
$103K ﹤0.01%
+600
New +$92.3K
NNA
2348
DELISTED
Navios Maritime Acquisition Corporation
NNA
$102K ﹤0.01%
+25,138
New +$95.8K
KLDO
2349
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$100K ﹤0.01%
+12,356
New +$135K
ATNM icon
2350
Actinium Pharmaceuticals
ATNM
$26.7M
$99K ﹤0.01%
13,019
-9,823
-43% -$83.4K

Similar funds

Marshall Wace's Q1 2021 Portfolio in Review

As of Q1 2021, Marshall Wace held 3,109 positions worth $21.8B, up 18% from $18.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.

Marshall Wace deployed $2.78B of net new capital in Q1 2021, opening 1,280 new positions and adding to 559 existing holdings. Its largest new stake was Paramount Global Class B: 5,936,494 shares worth $268M.

By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 28% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Thermo Fisher Scientific, an estimated $204M trimmed.

  • Marshall Wace's largest Q1 2021 buy was Paramount Global Class B: 5,936,494 shares worth $268M.
  • Marshall Wace added most to Farfetch Limited Class A Ordinary Shares in Q1 2021, an estimated $182M increase.
  • Marshall Wace's biggest Q1 2021 reduction was Thermo Fisher Scientific, cutting an estimated $204M.
  • Marshall Wace fully exited Vanguard Intermediate-Term Corporate Bond ETF in Q1 2021, selling an estimated $76.2M.
  • Marshall Wace's ten largest holdings make up 12% of its $21.8B portfolio in Q1 2021.
  • Marshall Wace opened 1,280 new positions and closed 699 in Q1 2021.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $21.8B.

Based on Marshall Wace's 13F filing for Q1 2021, filed 17 May 2021.